IMEL Biotherapeutics, is developing a cell-based therapy which represents a new paradigm for the treatment of patients with mitochondrial disorders. Using its proprietary Mitochondrial Replaced Cells technology, IMEL will enable to treat multiple patients with mitochondrial genetic or age-related disorders.
Additional Portfolio Companies
